NF155 autoimmunity study design

**Cohort 1**
Retrospective

- ICD-9, ICD-10 codes for demyelinating diseases (January 1st, 1986, to January 1st, 2019)
  - Manual chart review
    - CIDP (n=214), AIDP (n=23), non-CIDP/AIDP/CISP disease controls (n=173)

- NF155 IgG4/pan IgG tested in our lab, n=18 (NF155 IgG4, n=14, NF155 IgG, n=4)

**Cohort 2**
Prospective

- Clinically suspected NF155 cases seen in Mayo Peripheral Nerve Clinic (January 1st, 2019, to March 1st, 2021)
  - Manual chart review of all cases tested for NF155 autoantibodies

- NF155 IgG4/pan IgG tested on in-house assay/sent to outside facility lab for NF155 IgG4/pan IgG and NF155 IgM testing, n=14 (NF155 IgG4 n=6, NF155 IgG, n=1, NF155 IgM, n=7)

---

a Disease controls were tested

b Idiopathic length-dependent axonal peripheral neuropathies (n=36); motor neuron disease (n=13); structural cervical or lumbar polyradiculopathy (n=10); genetic neuropathies (n=4); small fiber neuropathy (n=4); microvasculitis (n=5); systemic autoimmune conditions (Lupus and Sjogren, n=46) and other demyelinating polyradiculoneuropathy (n=56)

c 5 NF155 IgG4 patients were tested in Mayo Neuroimmunology laboratory, 9 (NF155 IgM, n=7, NF155 IgG, n=1, NF155 IgG, n=1) were tested in Washington University Neuromuscular Laboratory

dFigure 1: Schematic representation of the two cohorts (retrospective and prospective) tested for Neurofascin 155 (NF155) antibodies.